Last reviewed · How we verify
Nicotine Replacement Therapy Agent
At a glance
| Generic name | Nicotine Replacement Therapy Agent |
|---|---|
| Also known as | Nicotine Patch, Nicotine Gum, Nicotine Lozenge |
| Sponsor | Centre for Addiction and Mental Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Metabolome and Gut Microbiome Changes During Smoking Cessation in Long-term Drug Therapy in a Therapeutic Community (NA)
- Smoking Cessation and Menstrual Cycle Phase (PHASE4)
- Cytisine vs Nicotine Replacement Therapy (NA)
- Auricular Stimulation for Nicotine Withdrawal in Psychiatric Inpatients (NA)
- Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment (PHASE4)
- E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder (PHASE2)
- Enhancing Smoking Cessation for African American People Everywhere (PHASE2)
- Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: